XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2022 $ 146,211 $ 232,368,121 $ (129,688,467) $ 102,825,865 $ 600,380 $ 103,426,245
Balance (in Shares) at Sep. 30, 2022   146,211,130          
Stock-based compensation expense 1,201,081 1,201,081 1,201,081
Net loss (3,593,645) (3,593,645) (3,593,645)
Balance at Dec. 31, 2022 $ 146,211 233,569,202 (133,282,112) 100,433,301 600,380 101,033,681
Balance (in Shares) at Dec. 31, 2022   146,211,130          
Issuance of common stock for services $ 100 101,900 102,000 102,000
Issuance of common stock for services (in Shares)   100,000          
Issuance of common stock upon exercise of stock options $ 47 31,220 31,267 31,267
Issuance of common stock upon exercise of stock options (in Shares)   46,667          
Stock-based compensation expense 1,165,595 1,165,595 1,165,595
Net loss (10,526,025) (10,526,025) (10,526,025)
Balance at Mar. 31, 2023 $ 146,358 234,867,917 (143,808,137) 91,206,138 600,380 91,806,518
Balance (in Shares) at Mar. 31, 2023   146,357,797          
Balance at Sep. 30, 2023 $ 158,858 252,903,629 (162,231,379) 90,831,108 600,380 91,431,488
Balance (in Shares) at Sep. 30, 2023   158,857,798          
Issuance of common stock for services $ 109 76,037 76,146 76,146
Issuance of common stock for services (in Shares)   108,778          
Stock-based compensation expense 3,058,185 3,058,185 3,058,185
Net loss (9,231,185) (9,231,185) (9,231,185)
Balance at Dec. 31, 2023 $ 158,967 256,037,851 (171,462,564) 84,734,254 600,380 85,334,634
Balance (in Shares) at Dec. 31, 2023   158,966,576          
Balance at Sep. 30, 2023 $ 158,858 252,903,629 (162,231,379) 90,831,108 600,380 $ 91,431,488
Balance (in Shares) at Sep. 30, 2023   158,857,798          
Issuance of common stock upon exercise of stock options (in Shares)            
Balance at Mar. 31, 2024 $ 159,095 259,214,194 (180,006,718) 79,366,571 600,380 $ 79,966,951
Balance (in Shares) at Mar. 31, 2024   159,094,781          
Balance at Dec. 31, 2023 $ 158,967 256,037,851 (171,462,564) 84,734,254 600,380 85,334,634
Balance (in Shares) at Dec. 31, 2023   158,966,576          
Issuance of common stock for services $ 128 97,951 98,079 98,079
Issuance of common stock for services (in Shares)   128,205          
Stock-based compensation expense 3,078,392 3,078,392 3,078,392
Net loss (8,544,154) (8,544,154) (8,544,154)
Balance at Mar. 31, 2024 $ 159,095 $ 259,214,194 $ (180,006,718) $ 79,366,571 $ 600,380 $ 79,966,951
Balance (in Shares) at Mar. 31, 2024   159,094,781